Q3 2022 13F Holders as of 9/30/2022
-
Type / Class
-
Equity / Common Stock, $0.001 par value
-
Shares outstanding
-
120M
-
Number of holders
-
38
-
Total 13F shares, excl. options
-
15.8M
-
Shares change
-
-733K
-
Total reported value, excl. options
-
$18.5M
-
Value change
-
-$594K
-
Number of buys
-
13
-
Number of sells
-
-16
-
Price
-
$1.17
Significant Holders of Aquestive Therapeutics, Inc. - Common Stock, $0.001 par value (AQST) as of Q3 2022
44 filings reported holding AQST - Aquestive Therapeutics, Inc. - Common Stock, $0.001 par value as of Q3 2022.
Aquestive Therapeutics, Inc. - Common Stock, $0.001 par value (AQST) has 38 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 15.8M shares
of 120M outstanding shares and own 13.18% of the company stock.
Largest 10 shareholders include Bratton Capital Management, L.P. (9.81M shares), VANGUARD GROUP INC (1.18M shares), RENAISSANCE TECHNOLOGIES LLC (901K shares), Vahanian & Associates Financial Planning Inc. (695K shares), MILLENNIUM MANAGEMENT LLC (476K shares), Bracebridge Capital, LLC (429K shares), Schonfeld Strategic Advisors LLC (407K shares), BlackRock Inc. (374K shares), GEODE CAPITAL MANAGEMENT, LLC (366K shares), and Latash Investments, LLC (243K shares).
This table shows the top 38 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.